Pharmaceuticals News and Research

RSS

Valeant, Biovail announce definitive merger agreement

Valeant today announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc.

21 Jun 2010

Study shows effective and efficient methods for producing recombinant proteins

A shift in the life science market has begun to steer cell culture scientists to re-evaluate their use of native transferrin and iron chelators to pursue recombinant alternatives. Transferrin regulates the uptake, transport and utilization of iron for cellular function, increasing cell growth and productivity. Native transferrin found in bovine or human serum has been widely used in cell culture for these added benefits. However, regulatory issues continue to arise with the use of native transferrin due to blood-borne pathogens.

21 Jun 2010

APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.

21 Jun 2010

Thomson Reuters' The Outpartnering Registry available for all organizations developing drugs

Thomson Reuters announced today that it has launched The Outpartnering Registry, an innovative resource designed to change the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around the world.

21 Jun 2010

European drug companies' lead in making medicines available to developing countries shrinking: Report

European pharmaceutical companies outcompete their U.S. counterparts in making medicines available to people in developing countries, but their lead is shrinking, according to the second Access to Medicine Index, released today.

21 Jun 2010

Pfizer Canada announces temporary suspension of Lipitor Continuity Card Program

The Regie d'Assurance Maladie du Quebec (RAMQ) recently advised Pfizer that they are examining all pharmaceutical card programs in Quebec. In light of this they have sent us a formal request dated June 16, 2010 to temporarily suspend the Lipitor Continuity Card Program. As part of our ongoing collaboration with the RAMQ, we have made the decision to temporarily suspend the distribution of the Lipitor Continuity Card in Quebec while they complete their analysis.

19 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA.

19 Jun 2010

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

Spectrum Pharmaceuticals, Inc. today announced that it has adjourned its Annual Meeting of Stockholders to 10:30a.m. Pacific Time, Thursday, July 1, 2010, which will be held at the Company's corporate office located at 157 Technology Drive, Irvine, California, 92618.

19 Jun 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 are convertible at the option of the holders and will remain convertible at least through July 19, 2010, as provided for in the Indenture governing the notes.

19 Jun 2010

DEA, Harvard Drug Group announce agreement to modify suspension

Today, the Drug Enforcement Administration and U.S. Attorney's Office, and Harvard Drug Group announced their agreement to immediately modify the suspension, upon certain conditions, of Harvard's registration to distribute schedule III through V controlled substances out of its Livonia Distribution Center, and a mutual commitment to commence discussions, towards resolution of the issues raised in the DEA's suspension order. The suspension remains as to schedule II controlled substances.

19 Jun 2010

Health Robotics announces new Canadian marketing contracts for i.v.STATION, i.v.SOFT

Health Robotics announced that its joint-venture Health Robotics Canada Inc. (HRCI), a leading Canadian Pharmaceutical Company, and a well-established Quebec-based Medical Device Technology company have all recently signed marketing agreements in order to expand into Canada the market presence of i.v.STATION and i.v.SOFT, revolutionary technologies that provide automated sterile compounding of intravenous medications and parenteral nutrition to hospitals.

19 Jun 2010

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

Montana Governor visits Cannabis Science's latest acquisition

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to report that Montana Governor Brian Schweitzer visited its latest acquisition, Montana Pain Management in Missoula, yesterday. Governor Schweitzer observed, "You are doing it right."

19 Jun 2010

Akela Pharma first-quarter net loss reduces to $0.4 million

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months ended March 31, 2010.

19 Jun 2010

HBSS reaches $103M settlement with Astra Zeneca

Hagens Berman Sobol Shapiro (HBSS) today announced it has reached a proposed $103 million settlement with Astra Zeneca (AZ) on behalf of consumers and third party purchasers. The class-action lawsuit claimed Astra Zeneca inflated the Average Wholesale Price (AWP), which is used as a benchmark for almost all prescription drug sales in the United States.

19 Jun 2010

Tongjitang first-quarter net revenue up 25.6% to $16.6 million

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended March 31, 2010.

19 Jun 2010

Teva closes $2.5 billion Senior Notes offering

Teva Pharmaceutical Industries Limited announced today that it has closed the previously announced offering, by its special purpose finance subsidiaries, of a debt offering in three tranches:

19 Jun 2010

Lawmakers want crackdown on drug agreements that keep generics out

Democrats are looking at proposals to crack down on licensing agreements between drug companies that keep generic drugs out of the market, Politico reports. In the agreements, pharmaceutical companies pay generic manufacturers to "delay introduction of generic drugs, which are often cheaper than brand-name drugs.

18 Jun 2010

Advisory panel recommends FDA approve new "morning after" pill

The New York Times: A Food and Drug Administration advisory panel Thursday recommended that the agency approve "a medicine that could help prevent pregnancy if taken as late as five days after unprotected sex. The pill, called ella, sprang from government labs and appears to be more effective than Plan B, a morning-after pill now available over the counter to women 18 and older that gradually loses efficacy after intercourse and can be taken at latest three days after sex.

18 Jun 2010

Pharmaceuticals News and Research

Valeant, Biovail announce definitive merger agreement

Study shows effective and efficient methods for producing recombinant proteins

APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP

Thomson Reuters' The Outpartnering Registry available for all organizations developing drugs

European drug companies' lead in making medicines available to developing countries shrinking: Report

Pfizer Canada announces temporary suspension of Lipitor Continuity Card Program

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

DEA, Harvard Drug Group announce agreement to modify suspension

Health Robotics announces new Canadian marketing contracts for i.v.STATION, i.v.SOFT

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

Montana Governor visits Cannabis Science's latest acquisition

Akela Pharma first-quarter net loss reduces to $0.4 million

HBSS reaches $103M settlement with Astra Zeneca

Tongjitang first-quarter net revenue up 25.6% to $16.6 million

Teva closes $2.5 billion Senior Notes offering

Lawmakers want crackdown on drug agreements that keep generics out

Advisory panel recommends FDA approve new "morning after" pill

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence